SCHEMBL19954572

SCHEMBL19954572

CC(C)c1cc(C(F)(F)F)nn1C1CCNC(=O)C1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.36
MAP3K12 Q12852 2/20 0.36
PLAT P00750 1/20 0.36
TACR1 P25103 1/20 0.34
NR3C2 P08235 1/20 0.33
PDE4B Q07343 2/20 0.32
PDE3A Q14432 2/20 0.32
KCNN4 O15554 1/20 0.32
TGFBR1 P36897 2/20 0.32
GRIA1 P42261 1/20 0.31
FLT3 P36888 1/20 0.31
SYK P43405 1/20 0.31
AURKB Q96GD4 1/20 0.31
SOS1 Q07889 1/20 0.31
PIM1 P11309 1/20 0.30
PIM3 Q86V86 1/20 0.30
PIM2 Q9P1W9 1/20 0.30
IRAK4 Q9NWZ3 1/20 0.30
KDM5B Q9UGL1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21023766 0.84 PLAT (0.38) MAPK1MAP3K12PLATTACR1NR3C2
SCHEMBL18161162 0.82 MAPK1 (0.37) MAPK1MAP3K12PIM1PIM3PIM2
SCHEMBL19954537 0.82 PLAT (0.42) MAP3K12PLATNR3C2TGFBR1IRAK4
SCHEMBL19954668 0.81 PLAT (0.36) MAPK1MAP3K12PLATTACR1NR3C2
SCHEMBL19954634 0.81 CRBN (0.35) MAP3K12PLATTACR1NR3C2PDE4B
SCHEMBL19105611 0.80 TGFBR1 (0.35) MAP3K12NR3C2KCNN4TGFBR1
SCHEMBL19954570 0.80 TGFBR1 (0.42) MAP3K12PLATTGFBR1
SCHEMBL19954553 0.77 NR3C2 (0.40) MAP3K12NR3C2TGFBR1
SCHEMBL19954663 0.77 NR3C2 (0.38) MAP3K12NR3C2KCNN4TGFBR1
SCHEMBL21024127 0.76 NR3C2 (0.40) MAP3K12NR3C2TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392350-B2 N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2019-08-27 US disclosed
US-20180222867-A1 N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION 2018-08-09 US disclosed
US-9914706-B2 N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10392350-B2 N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof ATP5F1A, ATP5ME, ATP5F1D MAPK1 2041/4885MAP3K12 1341/4885PLAT 2233/4885
US-20180222867-A1 N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5ME, ATP5F1D MAPK1 2041/4885MAP3K12 1341/4885PLAT 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.